Novartis AG Revenue 2010-2022 | NVS

Novartis AG annual/quarterly revenue history and growth rate from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Novartis AG revenue for the quarter ending March 31, 2022 was $12.814B, a 0.95% increase year-over-year.
  • Novartis AG revenue for the twelve months ending March 31, 2022 was $52.997B, a 6.24% increase year-over-year.
  • Novartis AG annual revenue for 2021 was $52.877B, a 5.97% increase from 2020.
  • Novartis AG annual revenue for 2020 was $49.898B, a 2.51% increase from 2019.
  • Novartis AG annual revenue for 2019 was $48.677B, a 5.59% increase from 2018.
Novartis AG Annual Revenue
(Millions of US $)
2021 $52,877
2020 $49,898
2019 $48,677
2018 $46,099
2017 $50,135
2016 $49,436
2015 $50,387
2014 $53,634
2013 $52,716
2012 $51,971
2011 $59,375
2010 $51,561
2009 $45,103
Novartis AG Quarterly Revenue
(Millions of US $)
2022-03-31 $12,814
2021-12-31 $17,460
2021-09-30 $9,429
2021-06-30 $13,294
2021-03-31 $12,694
2020-12-31 $16,783
2020-09-30 $8,785
2020-06-30 $11,622
2020-03-31 $12,708
2019-12-31 $12,716
2019-09-30 $12,482
2019-06-30 $12,024
2019-03-31 $11,455
2018-12-31 $11,897
2018-09-30 $11,386
2018-06-30 $11,653
2018-03-31 $11,163
2017-12-31 $13,164
2017-09-30 $12,692
2017-06-30 $12,494
2017-03-31 $11,785
2016-12-31 $12,606
2016-09-30 $12,341
2016-06-30 $12,679
2016-03-31 $11,810
2015-12-31 $12,804
2015-09-30 $12,485
2015-06-30 $12,896
2015-03-31 $12,202
2014-12-31 $13,354
2014-09-30 $13,300
2014-06-30 $13,949
2014-03-31 $13,031
2013-12-31 $12,324
2013-09-30 $12,906
2013-06-30 $13,280
2013-03-31 $14,206
2012-12-31 $9,478
2012-09-30 $14,039
2012-06-30 $14,541
2012-03-31 $13,913
2011-12-31 $14,996
2011-09-30 $15,034
2011-06-30 $15,123
2011-03-31 $14,222
2010-12-31 $14,464
2010-09-30 $12,820
2010-06-30 $11,921
2010-03-31 $12,356
2009-12-31 $13,145
2009-09-30 $11,290
2009-06-30 $10,742
2009-03-31 $9,926
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $196.117B $52.877B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $461.811B 17.76
Pfizer (PFE) United States $282.789B 9.86
Eli Lilly (LLY) United States $280.478B 33.09
AbbVie (ABBV) United States $269.361B 11.81
Merck (MRK) United States $232.903B 13.16
GlaxoSmithKline (GSK) United Kingdom $110.899B 12.95
Novo Nordisk (NVO) Denmark $0.000B 30.80